Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/90240/1/phco.31.3.312.pd
Background Clinical drug trials in patients with heart failure and preserved ejection fraction have ...
Heart failure (HF) with preserved ejection fraction (HFpEF) accounts for nearly half of the cases of...
AbstractHeart failure is currently a social welfare and economic burden. In particular, the prevalen...
Between 2013 and 2016 there were approximately 6.2 million adults in the United States living with h...
Heart failure, in its diverse forms based on the value of the ejection fraction, is associated to hi...
Heart failure with preserved ejection fraction (HFpEF) has a significant impact on healthcare resour...
Progressive aging of the population and prolongation of life expectancy have led to the rising preva...
permits unrestricted use, distribution, and reproduction in any medium, provided the original work i...
Examination of patients with reduced and preserved ejection fraction in the DIG (Digitalis Investiga...
Significant progress in our understanding of risk factors and interventions in heart failure, a lead...
The management of heart failure with reduced ejection fraction (HF-REF) has improved significantly o...
The management of heart failure with reduced ejection fraction (HF-REF) has improved significantly o...
Limited data exist describing the differences in the medical treatment of patients with heart failur...
AIMS: Heart failure with preserved ejection fraction (HFpEF) poses a substantial challenge for clini...
Background Clinical drug trials in patients with heart failure and preserved ejection fraction have ...
Background Clinical drug trials in patients with heart failure and preserved ejection fraction have ...
Heart failure (HF) with preserved ejection fraction (HFpEF) accounts for nearly half of the cases of...
AbstractHeart failure is currently a social welfare and economic burden. In particular, the prevalen...
Between 2013 and 2016 there were approximately 6.2 million adults in the United States living with h...
Heart failure, in its diverse forms based on the value of the ejection fraction, is associated to hi...
Heart failure with preserved ejection fraction (HFpEF) has a significant impact on healthcare resour...
Progressive aging of the population and prolongation of life expectancy have led to the rising preva...
permits unrestricted use, distribution, and reproduction in any medium, provided the original work i...
Examination of patients with reduced and preserved ejection fraction in the DIG (Digitalis Investiga...
Significant progress in our understanding of risk factors and interventions in heart failure, a lead...
The management of heart failure with reduced ejection fraction (HF-REF) has improved significantly o...
The management of heart failure with reduced ejection fraction (HF-REF) has improved significantly o...
Limited data exist describing the differences in the medical treatment of patients with heart failur...
AIMS: Heart failure with preserved ejection fraction (HFpEF) poses a substantial challenge for clini...
Background Clinical drug trials in patients with heart failure and preserved ejection fraction have ...
Background Clinical drug trials in patients with heart failure and preserved ejection fraction have ...
Heart failure (HF) with preserved ejection fraction (HFpEF) accounts for nearly half of the cases of...
AbstractHeart failure is currently a social welfare and economic burden. In particular, the prevalen...
DOI
Add to ORKG